Results 231 to 240 of about 24,092,998 (355)
Molecular Oncology, EarlyView.Clinical trials on PARP inhibitors in urothelial carcinoma (UC) showed limited efficacy and a lack of predictive biomarkers. We propose SLFN5, SLFN11, and OAS1 as UC‐specific response predictors. We suggest Talazoparib as the better PARP inhibitor for UC than Olaparib.
Jutta Schmitz +15 more
wiley +1 more source
All-Inside Anterior Cruciate Ligament Reconstruction With Bone-Patellar Tendon-Bone Autograft. [PDF]
Video J Sports Medvan der List JP +3 more
europepmc +1 more source
Cytoplasmic p21 promotes stemness of colon cancer cells via activation of the NFκB pathway
Molecular Oncology, EarlyView.Cytoplasmic p21 promotes colorectal cancer stem cell (CSC) features by destabilizing the NFκB–IκB complex, activating NFκB signaling, and upregulating BCL‐xL and COX2. In contrast to nuclear p21, cytoplasmic p21 enhances spheroid formation and stemness transcription factor CD133.
Arnatchai Maiuthed +10 more
wiley +1 more source
Posterior Hamstring Harvest and Preparation for Quadruple Autograft All-Inside Anterior Cruciate Ligament Reconstruction. [PDF]
Video J Sports Medvan der List JP, Backs R, Kaeding CC.
europepmc +1 more source
“All from us” or “All with us”: Addressing Precision Medicine Inequities Requires Inclusion of Intersectionally Minoritized Populations as Partners and Project Leaders [PDF]
John Noel M. Viaña
openalex +1 more source
Molecular Oncology, EarlyView.HDAC4 is degraded by the E3 ligase FBXW7. In colorectal cancer, FBXW7 mutations prevent HDAC4 degradation, leading to oxaliplatin resistance. Forced degradation of HDAC4 using a PROTAC compound restores drug sensitivity by resetting the super‐enhancer landscape, reprogramming the epigenetic state of FBXW7‐mutated cells to resemble oxaliplatin ...
Vanessa Tolotto +13 more
wiley +1 more source